Close Menu

CareDx

The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.

The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.

The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.

CareDx, which focuses on transplant medicine, said it intends to use the proceeds from the offering for working capital and general corporate purposes.

The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.

The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.

The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

The company reported $38.4 million in total revenues for the quarter and said testing services revenues rose 46 percent year over year.

The ALARM Partnership is being launched to measure the impact of AlloSure and RemoTraC on lung transplant patients.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.